NCT01636245View on ClinicalTrials.gov

Immunogenicity and Safety of Three Consecutive Lots of a New Inactivated Enterovirus Type 71 (EV71) Vaccine

PHASE3CompletedINTERVENTIONAL

Enrollment

1,400

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

February 28, 2013

Conditions

Hand, Foot and Mouth Disease

Interventions

BIOLOGICAL

three consecutive lots of EV71 vaccine

inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval

BIOLOGICAL

placebo

placebo, two doses, 28 days interval

Trial Locations (1)

Unknown

Jurong, Zhenjiang

All Listed Sponsors

lead

Sinovac Biotech Co., Ltd

INDUSTRY

NCT01636245 - Immunogenicity and Safety of Three Consecutive Lots of a New Inactivated Enterovirus Type 71 (EV71) Vaccine | Biotech Hunter | Biotech Hunter